Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Raghu Venkatramanamoorthy"'
Autor:
Mohammad Mobayed, Lance K. Heilbrun, Anthony F. Shields, Tara Washington, Raghu Venkatramanamoorthy, Philip A. Philip, Bassel F. El-Rayes
Publikováno v:
Case Reports in Oncology, Vol 2, Iss 3, Pp 220-228 (2009)
Background: Adjuvant 5-fluorouracil (5FU)-based chemo-radiotherapy is currently considered a standard of care for the treatment of gastric cancer. The impact of 5FU-based adjuvant therapy on the rate of distant recurrence has been modest. In order to
Externí odkaz:
https://doaj.org/article/fb5ecbb2082c4a8d8a31c5a6488f5e9f
Autor:
Raghu Venkatramanamoorthy, Anthony F. Shields, Philip A. Philip, Bassel F. El-Rayes, Mark M. Zalupski, Lance K. Heilbrun, Nazik Hammad
Publikováno v:
Asia-Pacific Journal of Clinical Oncology. 6:98-105
Aims: The aim of this study was to determine the predictive role of pretreatment carbohydrate antigen 19-9 (CA19-9) measurement and its change after one cycle of gemcitabine-based therapy for response, time to progression (TTP) and overall survival (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::02ea741dc3e7fc822becb6b0c842687f
https://doi.org/10.1111/j.1743-7563.2010.01290.x
https://doi.org/10.1111/j.1743-7563.2010.01290.x
Autor:
Lance K. Heilbrun, Mark M. Zalupski, Anthony F. Shields, Jawana M. Lawhorn-Crews, Raghu Venkatramanamoorthy, Minsig Choi
Publikováno v:
American Journal of Clinical Oncology. 33:257-261
Background: Pancreatic cancer ranks as the fourth leading cause of cancer death in the United States with 5-year survival ranging from 1% to 5%. Positron emission tomography (PET) is a metabolic imaging system that is widely used for the initial stag
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45a0ad44200b1631b62f520ff24c7353
https://doi.org/10.1097/coc.0b013e3181a76a0b
https://doi.org/10.1097/coc.0b013e3181a76a0b
Autor:
Anthony F. Shields, Bassel F. El-Rayes, Tara Washington, Philip A. Philip, Lance K. Heilbrun, Mohammad Mobayed, Raghu Venkatramanamoorthy
Publikováno v:
Case Reports in Oncology, Vol 2, Iss 3, Pp 220-228 (2009)
Case Reports in Oncology
Case Reports in Oncology
Background: Adjuvant 5-fluorouracil (5FU)-based chemo-radiotherapy is currently considered a standard of care for the treatment of gastric cancer. The impact of 5FU-based adjuvant therapy on the rate of distant recurrence has been modest. In order to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c20f331a80e6672880de570daa6ed5f9
http://www.karger.com/Article/FullText/250082
http://www.karger.com/Article/FullText/250082
Autor:
Zora Djuric, Raghu Venkatramanamoorthy, Lance K. Heilbrun, Omer Kucuk, Chandice Covington, Gang Chen, Jianwei Ren
Publikováno v:
Cancer Epidemiology, Biomarkers & Prevention. 16:1393-1399
Background: A change in diet is known to affect micronutrient levels in blood but to what extent diet can affect micronutrient levels in the breast is not yet well established. Methods: Healthy, premenopausal women with a family history of breast can
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12baef8043448ee3eb0bb1ee5c2e22f2
https://doi.org/10.1158/1055-9965.epi-06-0766
https://doi.org/10.1158/1055-9965.epi-06-0766
Autor:
Raghu Venkatramanamoorthy, Mark M. Zalupski, Lance K. Heilbrun, Bassel F. El-Rayes, Ulka N. Vaishampayan, Stephanie G. Manza, Anthony F. Shields, Philip A. Philip, Barbara Rusin, Ann Marie Ferris
Publikováno v:
Cancer Chemotherapy and Pharmacology. 61:283-289
The cyclooxygenase-2 (COX-2) enzyme plays a major role in tumor progression and resistance to chemotherapy. A Phase-II study was undertaken to determine the activity of a dose attenuated schedule of irinotecan, capecitabine, and the COX-2 inhibitor c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a5196e11e0ec25739fc0416f8e02e4a
https://doi.org/10.1007/s00280-007-0472-1
https://doi.org/10.1007/s00280-007-0472-1
Autor:
Raghu Venkatramanamoorthy, Mark M. Zalupski, Lance K. Heilbrun, Philip A. Philip, Volkan Adsay, Anthony F. Shields, Basil F. El-Rayes, Ulka N. Vaishampayan, Ann Marie Ferris
Publikováno v:
Investigational New Drugs. 23:583-590
Summary Background .P ancreatic cancer is amongst the most chemoresistant malignancies. Expression of the cyclooxygenase-2 (COX-2) enzyme plays a major role in tumor progression and resistance to therapy. A Phase II study was undertaken to determine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a09b5c0f1044b6ba347427db56fe121e
https://doi.org/10.1007/s10637-005-1028-z
https://doi.org/10.1007/s10637-005-1028-z
Autor:
Raghu Venkatramanamoorthy, Patricia LoRusso, Syed F. Zafar, Pallavi Jasti, Li Ding, Prakash Vishnu, Elisabeth I. Heath, Lance K. Heilbrun
BACKGROUND: Geriatric cancer patients (age 65 or older) comprise a majority of cancer cases in the United States, yet they are underrepresented in therapeutic clinical trials. It is therefore important to increase our understanding of their participa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7fffe8426edc5fc485d4bc20e99c6351
https://europepmc.org/articles/PMC3077761/
https://europepmc.org/articles/PMC3077761/
Autor:
Gregory P. Kalemkerian, Antoinette J. Wozniak, Raghu Venkatramanamoorthy, Shirish M. Gadgeel, John C. Ruckdeschel, Ruth Chaplen, Michael J. Kraut, Lance K. Heilbrun
Introduction The utility of two-drug chemotherapy regimens in elderly or performance status (PS 2) patients with advanced non-small cell lung cancer (NSCLC) remains to be established. Preclinical studies suggested that celecoxib, a Cyclooxygenase-2 i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f68cd365fe543e541228719c4a8cd61a
https://europepmc.org/articles/PMC3859308/
https://europepmc.org/articles/PMC3859308/
Autor:
Lance K. Heilbrun, Kimberly Belzer, Raghu Venkatramanamoorthy, Gregory P. Kalemkerian, Antoinette J. Wozniak, Shirish M. Gadgeel, Michael J. Kraut, Omer Kucuk
Publikováno v:
Clinical lung cancer. 8(5)
Purpose This phase II study evaluated the efficacy and toxicity of gemcitabine/paclitaxel given every 2 weeks in patients with advanced-stage non–small-cell lung cancer. Treatment with 1 previous chemotherapy regimen was allowed. Patients received
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a4fa28f7cbbefb1d8a7910e97d62a23e
https://pubmed.ncbi.nlm.nih.gov/17562230
https://pubmed.ncbi.nlm.nih.gov/17562230